Subtype
Intestinal Carcinoma
CI-CAN-00002922Explore in graph →
409 active trials5 approved drugs22 evidence items
- NCIt
- C227934
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002922Explore in graph →
Clinical trials
1,268 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (150)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02949219 | Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | unknown | Phase 2 | 41 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03992456 | Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer | unknown | Phase 2 | 12 | Academic and Community Cancer Research UnitedOTHER | 1 | May 21, 2024 |
| clinicaltrials |
| NCT03337087 | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | unknown | Phase 1 / Phase 2 | 18 | Academic and Community Cancer Research UnitedOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT04755920 | SGM-101 in Colorectal Brain Metastases.(SGM-CBM) | unknown | Phase 2 | 10 | Leiden University Medical CenterOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06206096 | PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC | unknown | Phase 2 | 40 | Chinese PLA General HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT04301557 | PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer | unknown | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT04096417 | Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations | unknown | Phase 2 | 14 | Academic and Community Cancer Research UnitedOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT06262581 | Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06171854 | caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.(ABACO) | unknown | Phase 2 | 33 | University of Campania Luigi VanvitelliOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT06017141 | Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study | unknown | Phase 2 | 80 | University of Kansas Medical CenterOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT04984369 | The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment | unknown | Phase 2 | 50 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT02560298 | Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer(InterAACT) | unknown | Phase 2 | 91 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05233332 | Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)(mCRC) | unknown | Phase 2 | 186 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | May 31, 2023 | clinicaltrials |
| NCT05799820 | QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC | unknown | Phase 2 | 60 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 25, 2023 | clinicaltrials |
| NCT05815290 | Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer | unknown | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05406206 | Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy | unknown | Phase 2 | 27 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT04582981 | Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer | unknown | Phase 2 | 136 | Fudan UniversityOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT04988191 | Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer | unknown | Phase 1 / Phase 2 | 44 | Peking UniversityOTHER | 1 | Aug 3, 2021 | clinicaltrials |
| NCT04508452 | A Phase II Prospective Trial of mXELOXIRI Reintroduction for mCRC | unknown | Phase 2 | 91 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT04621370 | A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer(PRIME-RT) | unknown | Phase 2 | 48 | Liz-Anne LewsleyOTHER | 0 | Nov 9, 2020 | clinicaltrials |
| NCT04475159 | Combined Neoadjuvant Systemic and PIPAC Therapy (NASPIT) for Patients With Colorectal Peritoneal Metastasis Eligible for CRS and HIPEC: A Prospective Phase II Trial | unknown | Phase 2 | 50 | Prof. Aviram NissanOTHER_GOV | 0 | Jul 17, 2020 | clinicaltrials |
| NCT04380103 | A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 106 | Chinese Academy of Medical SciencesOTHER | 1 | May 8, 2020 | clinicaltrials |
| NCT02161822 | Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients | unknown | Phase 2 | 60 | Samsung Medical CenterOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT03944252 | Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)(CARACAS) | unknown | Phase 2 | 54 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Jul 26, 2019 | clinicaltrials |
| NCT01047969 | Avoiding Surgery in Rectal Cancer After Pre-Operative Therapy | unknown | Phase 2 | 99 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 13, 2019 | clinicaltrials |
| NCT03823079 | Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia | unknown | Phase 2 | 50 | Fudan UniversityOTHER | 0 | Jan 30, 2019 | clinicaltrials |
| NCT01037049 | Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks | unknown | Phase 2 | 237 | Royal Marsden NHS Foundation TrustOTHER | 4 | Sep 17, 2018 | clinicaltrials |
| NCT02919878 | Neo-adjuvant Chemoradiotherapy Using Infusional Gemcitabine Followed by Surgery for Locally Advanced Rectal Cancer | unknown | Phase 2 | 25 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT03601598 | A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC | unknown | Phase 1 / Phase 2 | 41 | Harbin Medical UniversityOTHER | 0 | Jul 26, 2018 | clinicaltrials |
| NCT01348256 | Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma | unknown | Phase 2 | 58 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT02617134 | CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02839954 | CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT00754078 | A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy | unknown | Phase 2 | 58 | AHS Cancer Control AlbertaOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT02051868 | International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel(InterAACT) | unknown | Phase 2 | 80 | Royal Marsden NHS Foundation TrustOTHER | 3 | Nov 4, 2015 | clinicaltrials |
| NCT02376452 | Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients | unknown | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Mar 3, 2015 | clinicaltrials |
| NCT02268006 | IMRT-SIB and Capecitabine in Preoperative Rectal Cancer Treatment(BISER) | unknown | Phase 2 | 50 | Institute of Oncology LjubljanaOTHER | 1 | Oct 20, 2014 | clinicaltrials |
| NCT00410462 | Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma | unknown | Phase 2 | 118 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Aug 8, 2014 | clinicaltrials |
| NCT00669812 | High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma | unknown | Phase 2 | 60 | Cancer Research UKOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT01811277 | SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer | unknown | Phase 2 | 40 | Peking UniversityOTHER | 1 | Mar 15, 2013 | clinicaltrials |
| NCT01227239 | Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting | unknown | Phase 1 / Phase 2 | 45 | Japan Clinical Cancer Research OrganizationOTHER | 1 | Nov 27, 2012 | clinicaltrials |
| NCT01552967 | Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma(mXELOX) | unknown | Phase 2 | 30 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Mar 28, 2012 | clinicaltrials |
| NCT00964457 | Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients | unknown | Phase 2 | 60 | Copenhagen University Hospital at HerlevOTHER | 1 | Aug 25, 2009 | clinicaltrials |
| NCT00557713 | XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma | unknown | Phase 2 | 44 | Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socialsOTHER | 1 | Nov 14, 2007 | clinicaltrials |
| NCT00215722 | XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer | unknown | Phase 2 | 45 | Grupo de Investigacao do Cancro DigestivoOTHER | 1 | Apr 6, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Aug 22, 2024source: clinicaltrials